

Highlights of This Issue 1**EDITORIAL**

- 3** A Message from the New Editor-in-Chief
Napoleone Ferrara

SMALL MOLECULE THERAPEUTICS

- 5** Small-Molecule IAP Antagonists Sensitize Cancer Cells to TRAIL-Induced Apoptosis: Roles of XIAP and cIAPs
Darren Finlay, Mitchell Vamos, Marcos González-López, Robert J. Ardecky, Santhi Reddy Ganji, Hongbin Yuan, Ying Su, Trina R. Cooley, Curt T. Hauser, Kate Welsh, John C. Reed, Nicholas D.P. Cosford, and Kristiina Vuori
- 16** Synergistic Combination of Novel Tubulin Inhibitor ABI-274 and Vemurafenib Overcomes Vemurafenib Acquired Resistance in BRAF^{V600E} Melanoma
Jin Wang, Jianjun Chen, Duane D. Miller, and Wei Li
- 27** SC-60, a Dimer-Based Sorafenib Derivative, Shows a Better Anti-Hepatocellular Carcinoma Effect than Sorafenib in a Preclinical Hepatocellular Carcinoma Model
Wei-Tien Tai, Chung-Wai Shiau, Yong-Shi Li, Yao-Li Chen, Pei-Yi Chu, Jui-Wen Huang, Cheng-Yi Hsu, Yi-Chieh Hsu, Pei-Jer Chen, and Kuen-Feng Chen
- 37** Synergistic Activities of MET/RON Inhibitor BMS-777607 and mTOR Inhibitor AZD8055 to Polyploid Cells Derived from Pancreatic Cancer and Cancer Stem Cells
Jun-Ying Zeng, Sharad Sharma, Yong-Qing Zhou, Hang-Ping Yao, Xing Hu, Ruiwen Zhang, and Ming-Hai Wang
- 49** Lappaol F, a Novel Anticancer Agent Isolated from Plant *Arctium Lappa* L.
Qing Sun, Kanglun Liu, Xiaoling Shen, Weixin Jin, Lingyan Jiang, M. Saeed Sheikh, Yingjie Hu, and Ying Huang

- 60** Enhanced PI3K p110 α Signaling Confers Acquired Lapatinib Resistance That Can Be Effectively Reversed by a p110 α -Selective PI3K Inhibitor

Samuel W. Brady, Jian Zhang, Daniel Seok, Hai Wang, and Dihua Yu

LARGE MOLECULE THERAPEUTICS

- 71** Surface-Modified Nanoparticles Enhance Transurothelial Penetration and Delivery of Survivin siRNA in Treating Bladder Cancer
Darryl T. Martin, Jill M. Steinbach, Jingchun Liu, Shogo Shimizu, Hristos Z. Kaimakliotis, Marcia A. Wheeler, Adam B. Hittelman, W. Mark Saltzman, and Robert M. Weiss
- 82** Antitumor Effects of Immunotoxins Are Enhanced by Lowering HCK or Treatment with Src Kinase Inhibitors
Xiu-Fen Liu, Laiman Xiang, David J. FitzGerald, and Ira Pastan
- 90** Superior Antitumor Activity of a Novel Bispecific Antibody Cotargeting Human Epidermal Growth Factor Receptor 2 and Type I Insulin-like Growth Factor Receptor
Chao Chen, Yanyu Zhang, Yu Zhang, Jingjing Li, Sai Wah Tsao, and Mei-Yun Zhang
- 101** Tetravalent Antibody-scTRAIL Fusion Proteins with Improved Properties
Oliver Seifert, Aline Plappert, Sina Fellermeier, Martin Siegemund, Klaus Pfizenmaier, and Roland E. Kontermann
- 112** Combining Antibody-Directed Presentation of IL-15 and 4-1BBL in a Trifunctional Fusion Protein for Cancer Immunotherapy
Vanessa Kermer, Nora Hornig, Markus Harder, Anastasiia Bondarieva, Roland E. Kontermann, and Dafne Müller

Table of Contents

CANCER BIOLOGY AND SIGNAL TRANSDUCTION

- 122** **Response to MLN8237 in Pancreatic Cancer Is Not Dependent on RalA Phosphorylation**
Nicole F. Neel, Jeran K. Stratford, Vaishali Shinde, Jeffrey A. Ecsedy, Timothy D. Martin, Channing J. Der, and Jen Jen Yeh
- 134** **Off-Target Effects of c-MET Inhibitors on Thyroid Cancer Cells**
Yan Zhou, Conghui Zhao, Sigal Gery, Glenn D. Braunstein, Ryoko Okamoto, Rocío Alvarez, Steven A. Miles, Ngan B. Doan, Jonathan W. Said, Jiang Gu, and H. Phillip Koeffler
- 144** **Breaking the Invulnerability of Cancer Stem Cells: Two-Step Strategy to Kill the Stem-like Cell Subpopulation of Multiple Myeloma**
Agnieszka Morgenroth, Andreas T.J. Vogg, Boris D. Zlatopolskiy, Monika Siluschek, Caroline Oedekoven, and Felix M. Mottaghy
- 154** **Targeting Sphingosine Kinase Induces Apoptosis and Tumor Regression for KSHV-Associated Primary Effusion Lymphoma**
Zhiqiang Qin, Lu Dai, Jimena Trillo-Tinoco, Can Senkal, Wenxue Wang, Tom Reske, Karlie Bonstaff, Luis Del Valle, Paulo Rodriguez, Erik Flemington, Christina Voelkel-Johnson, Charles D. Smith, Besim Ogretmen, and Chris Parsons
- 165** **Hypoxia-Regulated Overexpression of Soluble VEGFR2 Controls Angiogenesis and Inhibits Tumor Growth**
Guillaume Collet, Nathalie Lamerant-Fayel, Magdalena Tertil, Bouchra El Hafny-Rahbi, Jacek Stepniewski, Alan Guichard, Alexandra Foucault-Collet, Krzysztof Klimkiewicz, Stéphane Petoud, Agata Matejuk, Catherine Grillon, Alicja Jozkowicz, Jozef Dulak, and Claudine Kieda
- 179** **Reversible Action of Diaminotiazoles in Cancer Cells Is Implicated by the Induction of a Fast Conformational Change of Tubulin and Suppression of Microtubule Dynamics**
Nisha E. Thomas, Reshma Thamkachy, Krishnankutty C. Sivakumar, Krishnakumar J. Sreedevi, Xavier Lieben Louis, Sannu A. Thomas, Rohith Kumar, Kallikat N. Rajasekharan, Lynne Cassimeris, and Suparna Sengupta
- 190** **Phosphoproteomic Profiling Identifies Focal Adhesion Kinase as a Mediator of Docetaxel Resistance in Castrate-Resistant Prostate Cancer**
Brian Y. Lee, Falko Hochgräfe, Hui-Ming Lin, Lesley Castillo, Jianmin Wu, Mark J. Raftery, S. Martin Shreeve, Lisa G. Horvath, and Roger J. Daly
- 202** **Differential Therapeutic Effects of Anti-VEGF-A Antibody in Different Tumor Models: Implications for Choosing Appropriate Tumor Models for Drug Testing**
Dror Alishekevitz, Rotem Brill, David Loven, Valeria Miller, Tali Voloshin, Svetlana Gingis-Velistki, Ella Fremder, Stefan J. Scherer, and Yuval Shaked
- 214** **Differential and Common DNA Repair Pathways for Topoisomerase I- and II-Targeted Drugs in a Genetic DT40 Repair Cell Screen Panel**
Yuko Maede, Hiroyasu Shimizu, Toru Fukushima, Toshiaki Kogame, Terukazu Nakamura, Tsuneharu Miki, Shunichi Takeda, Yves Pommier, and Junko Murai
- 221** **Sorafenib Suppresses JNK-Dependent Apoptosis through Inhibition of ZAK**
Harina Vin, Grace Ching, Sandra S. Ojeda, Charles H. Adelman, Vida Chitsazzadeh, David W. Dwyer, Haiching Ma, Karin Ehrenreiter, Manuela Baccarini, Rosamaria Ruggieri, Jonathan L. Curry, Ana M. Ciurea, Madeleine Duvic, Naifa L. Busaidy, Nizar M. Tannir, and Kenneth Y. Tsai
- 230** **Protein-Tyrosine Phosphatase H1 Increases Breast Cancer Sensitivity to Antiestrogens by Dephosphorylating Estrogen Receptor at Tyr537**
Padmanaban S. Suresh, Shao Ma, Antimo Migliaccio, and Guan Chen
- 239** **The Natural Inhibitor of DNA Topoisomerase I, Camptothecin, Modulates HIF-1 α Activity by Changing miR Expression Patterns in Human Cancer Cells**
Davide Bertozzi, Jessica Marinello, Stefano G. Manzo, Francesca Fornari, Laura Gramantieri, and Giovanni Capranico

Table of Contents

COMPANION DIAGNOSTICS AND CANCER BIOMARKERS

- 249** **MRP1 Overexpression Determines Poor Prognosis in Prospectively Treated Patients with Localized High-Risk Soft Tissue Sarcoma of Limbs and Trunk Wall: An ISG/GEIS Study**



Javier Martin-Broto, Antonio M. Gutierrez, Rafael F. Ramos, José A. Lopez-Guerrero, Stefano Ferrari, Silvia Stacchiotti, Piero Picci, Silvia Calabuig, Paola Collini, Marco Gambarotti, Silvia Bague, Angelo P. Dei Tos, Elena Palassini, Pablo Luna, Josefina Cruz, Ricardo Cubedo, Javier Martinez-Trufero, Andres Poveda, Paolo G. Casali, Antonio Fernandez-Serra, Antonio Lopez-Pousa, and Alessandro Gronchi

- 260** **Proteomics of Cancer Cell Lines Resistant to Microtubule-Stabilizing Agents**

Jakob Albrethsen, Ruth H. Angeletti, Susan Band Horwitz, and Chia-Ping Huang Yang

CORRECTIONS

- 270** **Correction: Chemotherapy Counteracts Metastatic Dissemination Induced by Antiangiogenic Treatment in Mice**


- 271** **Correction: MicroRNA Regulation of Oncolytic Adenovirus 6 for Selective Treatment of Castration-Resistant Prostate Cancer**

 AC icon indicates Author Choice

For more information please visit www.aacrjournals.org

ABOUT THE COVER

TRAIL is a potent inducer of apoptosis through activation of death receptors expressed on tumor cells. To improve the therapeutic activity of TRAIL, a novel tetravalent, bifunctional fusion protein was generated composed of single-chain Fv for targeted delivery (shown in blue), the IgE heavy chain domain 2 (EHD2) as covalently linked homodimerization module (shown in green), and a single-chain derivative of TRAIL as effector moiety (shown in red). Potent antitumoral effects were demonstrated for this scFv-EHD2-scTRAIL fusion protein *in vitro* and *in vivo*, further establishing the advantages of combining tumor targeting with dimeric presentation of scTRAIL. For details, see article by Seifert and colleagues on page 101.



Molecular Cancer Therapeutics

13 (1)

Mol Cancer Ther 2014;13:1-271.

Updated version Access the most recent version of this article at:
<http://mct.aacrjournals.org/content/13/1>

E-mail alerts [Sign up to receive free email-alerts](#) related to this article or journal.

Reprints and Subscriptions To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions To request permission to re-use all or part of this article, use this link <http://mct.aacrjournals.org/content/13/1>.
Click on "Request Permissions" which will take you to the Copyright Clearance Center's (CCC) Rightslink site.